TY - JOUR
T1 - Blood pressure and cardiovascular effects of new and emerging antidiabetic agents
AU - Balfour, Pelbreton C.
AU - Rodriguez, Carlos J.
AU - Ferdinand, Keith C.
N1 - Funding Information:
Carlos J. Rodriguez has received grants from the NIH/NHLBI (R01 HL104199 and R01HL104199-03S1).
PY - 2014/8
Y1 - 2014/8
N2 - Despite remarkable declines in US cardiovascular disease morbidity and mortality over the last several decades, the prevalence of risk factors such as type 2 diabetes and hypertension remains high, associated with increasing obesity rates. Although optimal glycemic control remains a primary focus to decrease the disease burden, the FDA has issued guidance recommendations for documenting cardiovascular disease-related safety with research trials on new antidiabetic agents with more demanding requirements compared to past approval of existing therapies. This review will discuss the public health impact of type 2 diabetes, specifically with comorbid hypertension; mechanisms of action of the newest antidiabetic drug classes; and preliminary findings and potential clinical significance of the favorable blood pressure and body weight effects of the sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists; and additionally discuss two recent large cardiovascular outcome trials with dipeptidyl peptidase-4 inhibitors.
AB - Despite remarkable declines in US cardiovascular disease morbidity and mortality over the last several decades, the prevalence of risk factors such as type 2 diabetes and hypertension remains high, associated with increasing obesity rates. Although optimal glycemic control remains a primary focus to decrease the disease burden, the FDA has issued guidance recommendations for documenting cardiovascular disease-related safety with research trials on new antidiabetic agents with more demanding requirements compared to past approval of existing therapies. This review will discuss the public health impact of type 2 diabetes, specifically with comorbid hypertension; mechanisms of action of the newest antidiabetic drug classes; and preliminary findings and potential clinical significance of the favorable blood pressure and body weight effects of the sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists; and additionally discuss two recent large cardiovascular outcome trials with dipeptidyl peptidase-4 inhibitors.
KW - Antidiabetic drugs
KW - Cardiovascular disease
KW - Diabetes
KW - Dipeptidyl peptidase-4 inhibitors
KW - Glucagon-like peptide-1 receptor agonists
KW - Hypertension
KW - Obesity
KW - Sodium-glucose cotransporter 2 inhibitors
KW - Systolic blood pressure
UR - http://www.scopus.com/inward/record.url?scp=84901859345&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901859345&partnerID=8YFLogxK
U2 - 10.1007/s11906-014-0455-7
DO - 10.1007/s11906-014-0455-7
M3 - Review article
C2 - 24908134
AN - SCOPUS:84901859345
SN - 1522-6417
VL - 16
JO - Current Hypertension Reports
JF - Current Hypertension Reports
IS - 8
M1 - 455
ER -